

W is NHC(=X)R₁, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection

(b);

Y is NH, O, or S;

Z is S(=O)(=N-R₅);

R₁ is

- (a) H,
- (b) NH₂,
- (c) NHC₁₋₄alkyl,
- (d) C₁₋₄alkyl,
- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or
- (h) (CH₂)_p C₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (c) C(=O)C₁₋₄alkyl,

(d) $C(=O)OC_{1-4}alkyl$,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

R_6 is H, $C_{1-4}alkyl$, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO_2 ,

phenyl, $C_{3-6}cycloalkyl$, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$,

$NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7 , oxo, or oxime;

R_7 is H, $C_{1-4}alkyl$, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF_3 , CH_3 , CN, NO_2 ,

phenyl, $C_{3-6}cycloalkyl$, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$,

$NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7 ;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the

group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered

heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;


j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3.

9. (ONCE AMENDED) A compound of claim 2-7 wherein X is an oxygen atom.


16. (ONCE AMENDED) A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

47. (ONCE AMENDED) A compound of formula II


C4
E1
cont




II

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



B is




W is $\text{NHC}(=\text{X})\text{R}_1$, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is $\text{S}(=\text{O})(=\text{N}-\text{R}_5)$ and the B ring has the following stereochemistry



R_1 is

- (a) H,
- (b) NH_2 ,
- (c) $\text{NHC}_{1-4}\text{alkyl}$,

- C₄
E₁
cont
- (d) C₁₋₄alkyl,
 - (e) C₂₋₄alkenyl,
 - (f) OC₁₋₄alkyl,
 - (g) SC₁₋₄alkyl, or
 - (h) (CH₂)_p C₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (a) H,
- (b) C₁₋₄alkyl,
- (c) C(=O)C₁₋₄alkyl,
- (d) C(=O)OC₁₋₄alkyl,
- (e) C(=O)NHR₆, or
- (f) C(=S)NHR₆;

R₆ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF₃ CH₃, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2.

C5 54. (ONCE AMENDED) The compound of claim 47 wherein X is an oxygen atom.

C6
E1
cont
65. (TWICE AMENDED) A compound of claim 47 which is

N-((5S)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (Z)-isomer;

N-((5S)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (Z)-isomer;

N-((5S)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide (Z)-isomer;

N-((5S)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanethioamide (Z)-isomer;

N-((5S)-3-[3-fluoro-4-[1-(acetyl-imino)-1-oxido-1,3-oxazolidin-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(methyl-imino)-1-oxido-1,3-oxazolidin-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(acetyl-imino)-1-oxido-1,3-oxazolidin-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(ethyl-imino)-1-oxido-1,3-oxazolidin-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxido-1,3-oxazolidin-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxido-1,3-oxazolidin-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(methylamino)carbonyl]imino)-1-oxido-1,3-oxazolidin-5-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1,3-oxazolidin-5-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;